



SYNAGEVA BIOPHARMA APPOINTS LEADING CLINICIAN AND INDUSTRY EXECUTIVE, DR. MARK GOLDBERG, TO ITS BOARD OF DIRECTORS

WALTHAM, Mass., October 10, 2008 -- [Synageva BioPharma](#) announced today the appointment of Mark Goldberg, M.D., Senior Vice President of Clinical Research at Genzyme Corp., and a leading medical oncologist and hematologist, to the Company's Board of Directors.

"In addition to his accomplished medical background, Mark is a seasoned industry executive and his direct experience in overseeing the development of Genzyme's products will make his strategic guidance an invaluable asset to the Synageva Board," said Felix J. Baker, Ph.D., Chairman of the Synageva Board and Managing Partner at Baker Brothers Investments.

"Having worked very closely with Dr Goldberg for almost 10 years at Genzyme, I am confident Mark will provide critical insight into the execution of our clinical development and product commercialization strategies," said Sanj K. Patel, President and Chief Executive Officer at Synageva. "Our proprietary [Protein Expression System](#) is enabling us to generate a diverse pipeline of follow-on, next-generation and novel monoclonal antibodies, cytokines and other biopharmaceuticals. These products are intended for use in a variety of therapeutic areas such as oncology, autoimmune and metabolic disorders. Mark's extensive clinical development experience in these areas and others will be instrumental as Synageva provides alternative and improved products for patients around the world."

Mark Goldberg, M.D. first joined Genzyme in 1996 as Medical Director for Oncology and following several promotions, has held his current position of Senior Vice President Clinical Research since 2000. Dr. Goldberg is a board-certified medical oncologist and hematologist. Prior to working at Genzyme, he was a full-time staff physician at Brigham and Women's Hospital and Dana Farber Cancer Institute, where he still holds appointments. Dr. Goldberg is an Associate Professor of Medicine at Harvard Medical School and is an author on more than 50 published papers. Dr. Goldberg received his A.B. (magna cum laude) from Harvard College and his M.D. (cum laude) from Harvard Medical School.

About Synageva BioPharma

Synageva BioPharma is focused on the development of biopharmaceuticals that address the needs of a global patient population in multiple areas, including oncology, autoimmune diseases and metabolic diseases.

Synageva™ has created sustainable value through its robust and cost-effective protein expression technology, AES™. We have generated a diverse pipeline of follow-on products as well as next-generation products that may exhibit superior efficacy and safety profiles. www.synageva.com

Contacts:

James E. Early SVP, Finance and Administration Synageva BioPharma (781) 890-1111	Media: Kari Watson MacDougall Biomedical Communications (781) 235-3060 kwatson@macbiocom.com
---	--

###